AXL–GAS6 expression can predict for adverse prognosis in non-small cell lung cancer with brain metastases

Xiaoliang Wu, Wenjuan Ma, Qianghua Zhou, Haijuan Yan, Zuan Fu Lim, Mayan Huang, Chuangzhong Deng, Xingsu Yu, Huifang Su, Satoshi Komo, Haixia Yang, Xinke Zhang, Sijin Wen, Zhenfeng Zhang, Patrick Chi-Chung Ma

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Purpose: Patients with non-small cell lung cancer (NSCLC) brain metastases (BM) have poor clinical outcomes. We sought to determine if AXL–GAS6 expression can be used as independent prognostic biomarkers for NSCLC BM. Methods: We retrospectively studied the medical records of 98 patients diagnosed with advanced metastatic NSCLC from December 2000 to June 2014. Out of a total of 98 patients with NSCLC metastases, 66 patients were identified to have brain metastases. The expressions of AXL and GAS6 were assessed by standard immunohistochemistry and correlated with clinicopathological factors and overall survival (OS) outcomes. Results: The expression of AXL was positively associated with GAS6 expression (P < 0.001), and tumor differentiation (P = 0.014) in advanced NSCLC with metastases. AXL expression displayed no association with gender, age, smoking history, pathology, T stage, N stage, CEA, and LDH. In univariate analysis, both AXL and GAS6 were found to predict worse OS outcomes (AXL: HR 1.77, 95% CI 1.13–2.79, P = 0.01; GAS6: HR 1.80, 95% CI 1.14–2.84, P = 0.01). In the brain metastasis subgroup, the expression of AXL was positively associated with GAS6 expression (P < 0.001). Both AXL and GAS6 were found to predict worse BM-OS outcomes in univariate analysis (AXL: HR 2.19, 95% CI 1.33–4.10, P = 0.005; GAS6: HR 2.04, 95% CI 1.01–3.71, P = 0.019). In multivariate analysis, high co-expression of AXL/GAS6 was found to be an independent unfavorable risk factor for the overall study population (HR 2.33, 95% CI 1.40–3.87, P = 0.0011) and also in BM (HR 2.76, 95% CI 1.45–5.25, P = 0.001), predicting worse survival outcome. Conclusions: AXL–GAS6 co-expression represents a potential independent prognostic biomarker for survival outcome in NSCLC BM patients.

Original languageEnglish (US)
Pages (from-to)1947-1957
Number of pages11
JournalJournal of Cancer Research and Clinical Oncology
Volume143
Issue number10
DOIs
StatePublished - Oct 1 2017

Fingerprint

Non-Small Cell Lung Carcinoma
Brain Neoplasms
Neoplasm Metastasis
Survival
Brain
Biomarkers
Medical Records
Multivariate Analysis
Smoking
History
Immunohistochemistry
Pathology
Population

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Wu, Xiaoliang ; Ma, Wenjuan ; Zhou, Qianghua ; Yan, Haijuan ; Lim, Zuan Fu ; Huang, Mayan ; Deng, Chuangzhong ; Yu, Xingsu ; Su, Huifang ; Komo, Satoshi ; Yang, Haixia ; Zhang, Xinke ; Wen, Sijin ; Zhang, Zhenfeng ; Ma, Patrick Chi-Chung. / AXL–GAS6 expression can predict for adverse prognosis in non-small cell lung cancer with brain metastases. In: Journal of Cancer Research and Clinical Oncology. 2017 ; Vol. 143, No. 10. pp. 1947-1957.
@article{5647f4ed8cc9429bb29d2cade1f57451,
title = "AXL–GAS6 expression can predict for adverse prognosis in non-small cell lung cancer with brain metastases",
abstract = "Purpose: Patients with non-small cell lung cancer (NSCLC) brain metastases (BM) have poor clinical outcomes. We sought to determine if AXL–GAS6 expression can be used as independent prognostic biomarkers for NSCLC BM. Methods: We retrospectively studied the medical records of 98 patients diagnosed with advanced metastatic NSCLC from December 2000 to June 2014. Out of a total of 98 patients with NSCLC metastases, 66 patients were identified to have brain metastases. The expressions of AXL and GAS6 were assessed by standard immunohistochemistry and correlated with clinicopathological factors and overall survival (OS) outcomes. Results: The expression of AXL was positively associated with GAS6 expression (P < 0.001), and tumor differentiation (P = 0.014) in advanced NSCLC with metastases. AXL expression displayed no association with gender, age, smoking history, pathology, T stage, N stage, CEA, and LDH. In univariate analysis, both AXL and GAS6 were found to predict worse OS outcomes (AXL: HR 1.77, 95{\%} CI 1.13–2.79, P = 0.01; GAS6: HR 1.80, 95{\%} CI 1.14–2.84, P = 0.01). In the brain metastasis subgroup, the expression of AXL was positively associated with GAS6 expression (P < 0.001). Both AXL and GAS6 were found to predict worse BM-OS outcomes in univariate analysis (AXL: HR 2.19, 95{\%} CI 1.33–4.10, P = 0.005; GAS6: HR 2.04, 95{\%} CI 1.01–3.71, P = 0.019). In multivariate analysis, high co-expression of AXL/GAS6 was found to be an independent unfavorable risk factor for the overall study population (HR 2.33, 95{\%} CI 1.40–3.87, P = 0.0011) and also in BM (HR 2.76, 95{\%} CI 1.45–5.25, P = 0.001), predicting worse survival outcome. Conclusions: AXL–GAS6 co-expression represents a potential independent prognostic biomarker for survival outcome in NSCLC BM patients.",
author = "Xiaoliang Wu and Wenjuan Ma and Qianghua Zhou and Haijuan Yan and Lim, {Zuan Fu} and Mayan Huang and Chuangzhong Deng and Xingsu Yu and Huifang Su and Satoshi Komo and Haixia Yang and Xinke Zhang and Sijin Wen and Zhenfeng Zhang and Ma, {Patrick Chi-Chung}",
year = "2017",
month = "10",
day = "1",
doi = "10.1007/s00432-017-2408-4",
language = "English (US)",
volume = "143",
pages = "1947--1957",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "10",

}

Wu, X, Ma, W, Zhou, Q, Yan, H, Lim, ZF, Huang, M, Deng, C, Yu, X, Su, H, Komo, S, Yang, H, Zhang, X, Wen, S, Zhang, Z & Ma, PC-C 2017, 'AXL–GAS6 expression can predict for adverse prognosis in non-small cell lung cancer with brain metastases', Journal of Cancer Research and Clinical Oncology, vol. 143, no. 10, pp. 1947-1957. https://doi.org/10.1007/s00432-017-2408-4

AXL–GAS6 expression can predict for adverse prognosis in non-small cell lung cancer with brain metastases. / Wu, Xiaoliang; Ma, Wenjuan; Zhou, Qianghua; Yan, Haijuan; Lim, Zuan Fu; Huang, Mayan; Deng, Chuangzhong; Yu, Xingsu; Su, Huifang; Komo, Satoshi; Yang, Haixia; Zhang, Xinke; Wen, Sijin; Zhang, Zhenfeng; Ma, Patrick Chi-Chung.

In: Journal of Cancer Research and Clinical Oncology, Vol. 143, No. 10, 01.10.2017, p. 1947-1957.

Research output: Contribution to journalArticle

TY - JOUR

T1 - AXL–GAS6 expression can predict for adverse prognosis in non-small cell lung cancer with brain metastases

AU - Wu, Xiaoliang

AU - Ma, Wenjuan

AU - Zhou, Qianghua

AU - Yan, Haijuan

AU - Lim, Zuan Fu

AU - Huang, Mayan

AU - Deng, Chuangzhong

AU - Yu, Xingsu

AU - Su, Huifang

AU - Komo, Satoshi

AU - Yang, Haixia

AU - Zhang, Xinke

AU - Wen, Sijin

AU - Zhang, Zhenfeng

AU - Ma, Patrick Chi-Chung

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Purpose: Patients with non-small cell lung cancer (NSCLC) brain metastases (BM) have poor clinical outcomes. We sought to determine if AXL–GAS6 expression can be used as independent prognostic biomarkers for NSCLC BM. Methods: We retrospectively studied the medical records of 98 patients diagnosed with advanced metastatic NSCLC from December 2000 to June 2014. Out of a total of 98 patients with NSCLC metastases, 66 patients were identified to have brain metastases. The expressions of AXL and GAS6 were assessed by standard immunohistochemistry and correlated with clinicopathological factors and overall survival (OS) outcomes. Results: The expression of AXL was positively associated with GAS6 expression (P < 0.001), and tumor differentiation (P = 0.014) in advanced NSCLC with metastases. AXL expression displayed no association with gender, age, smoking history, pathology, T stage, N stage, CEA, and LDH. In univariate analysis, both AXL and GAS6 were found to predict worse OS outcomes (AXL: HR 1.77, 95% CI 1.13–2.79, P = 0.01; GAS6: HR 1.80, 95% CI 1.14–2.84, P = 0.01). In the brain metastasis subgroup, the expression of AXL was positively associated with GAS6 expression (P < 0.001). Both AXL and GAS6 were found to predict worse BM-OS outcomes in univariate analysis (AXL: HR 2.19, 95% CI 1.33–4.10, P = 0.005; GAS6: HR 2.04, 95% CI 1.01–3.71, P = 0.019). In multivariate analysis, high co-expression of AXL/GAS6 was found to be an independent unfavorable risk factor for the overall study population (HR 2.33, 95% CI 1.40–3.87, P = 0.0011) and also in BM (HR 2.76, 95% CI 1.45–5.25, P = 0.001), predicting worse survival outcome. Conclusions: AXL–GAS6 co-expression represents a potential independent prognostic biomarker for survival outcome in NSCLC BM patients.

AB - Purpose: Patients with non-small cell lung cancer (NSCLC) brain metastases (BM) have poor clinical outcomes. We sought to determine if AXL–GAS6 expression can be used as independent prognostic biomarkers for NSCLC BM. Methods: We retrospectively studied the medical records of 98 patients diagnosed with advanced metastatic NSCLC from December 2000 to June 2014. Out of a total of 98 patients with NSCLC metastases, 66 patients were identified to have brain metastases. The expressions of AXL and GAS6 were assessed by standard immunohistochemistry and correlated with clinicopathological factors and overall survival (OS) outcomes. Results: The expression of AXL was positively associated with GAS6 expression (P < 0.001), and tumor differentiation (P = 0.014) in advanced NSCLC with metastases. AXL expression displayed no association with gender, age, smoking history, pathology, T stage, N stage, CEA, and LDH. In univariate analysis, both AXL and GAS6 were found to predict worse OS outcomes (AXL: HR 1.77, 95% CI 1.13–2.79, P = 0.01; GAS6: HR 1.80, 95% CI 1.14–2.84, P = 0.01). In the brain metastasis subgroup, the expression of AXL was positively associated with GAS6 expression (P < 0.001). Both AXL and GAS6 were found to predict worse BM-OS outcomes in univariate analysis (AXL: HR 2.19, 95% CI 1.33–4.10, P = 0.005; GAS6: HR 2.04, 95% CI 1.01–3.71, P = 0.019). In multivariate analysis, high co-expression of AXL/GAS6 was found to be an independent unfavorable risk factor for the overall study population (HR 2.33, 95% CI 1.40–3.87, P = 0.0011) and also in BM (HR 2.76, 95% CI 1.45–5.25, P = 0.001), predicting worse survival outcome. Conclusions: AXL–GAS6 co-expression represents a potential independent prognostic biomarker for survival outcome in NSCLC BM patients.

UR - http://www.scopus.com/inward/record.url?scp=85019739938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019739938&partnerID=8YFLogxK

U2 - 10.1007/s00432-017-2408-4

DO - 10.1007/s00432-017-2408-4

M3 - Article

C2 - 28551766

AN - SCOPUS:85019739938

VL - 143

SP - 1947

EP - 1957

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 10

ER -